Remifentanil Hydrochloride Patent Expiration
Remifentanil Hydrochloride was first introduced by Mylan Institutional Llc
Remifentanil Hydrochloride Patents
Given below is the list of patents protecting Remifentanil Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ultiva |
US5866591 (Pediatric) | Stable formulations of remifentanil |
Mar 10, 2018
(Expired) | Mylan Institutional |
| Ultiva | US5866591 | Stable formulations of remifentanil |
Sep 10, 2017
(Expired) | Mylan Institutional |
Remifentanil Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Remifentanil Hydrochloride Generic API Manufacturers
Several generic applications have been filed for Remifentanil Hydrochloride. The first generic version for Remifentanil Hydrochloride was by Fresenius Kabi Usa Llc and was approved on Jan 16, 2018. And the latest generic version is by Nivagen Pharmaceuticals Inc and was approved on Jun 28, 2024.
Given below is the list of companies who have filed for Remifentanil Hydrochloride generic, along with the locations of their manufacturing plants worldwide.
1. FRESENIUS KABI USA
Fresenius Kabi Usa Llc has filed for 3 different strengths of generic version for Remifentanil Hydrochloride. Given below are the details of the strengths of this generic introduced by Fresenius Kabi Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 1MG BASE/VIAL | injectable | Prescription | INJECTION | AP | Jan 16, 2018 |
| EQ 2MG BASE/VIAL | injectable | Prescription | INJECTION | AP | Jan 16, 2018 |
| EQ 5MG BASE/VIAL | injectable | Prescription | INJECTION | AP | Jan 16, 2018 |
Manufacturing Plant Locations New
Fresenius Kabi Usa's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Fresenius Kabi Usa as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
2. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Remifentanil Hydrochloride. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 1MG BASE/VIAL | injectable | Prescription | INJECTION | AP | Oct 13, 2020 |
| EQ 2MG BASE/VIAL | injectable | Prescription | INJECTION | AP | Oct 13, 2020 |
| EQ 5MG BASE/VIAL | injectable | Prescription | INJECTION | AP | Oct 13, 2020 |
Manufacturing Plant Locations New
Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
| Portugal |
| |||||||||
| Jordan |
| |||||||||
3. NIVAGEN PHARMS INC
Nivagen Pharmaceuticals Inc has filed for 3 different strengths of generic version for Remifentanil Hydrochloride. Given below are the details of the strengths of this generic introduced by Nivagen Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 1MG BASE/VIAL | injectable | Prescription | INJECTION | AP | Jun 28, 2024 |
| EQ 2MG BASE/VIAL | injectable | Prescription | INJECTION | AP | Jun 28, 2024 |
| EQ 5MG BASE/VIAL | injectable | Prescription | INJECTION | AP | Jun 28, 2024 |